Biocon Board to Consider Investment in Biocon Biologics

Biocon Ltd's Board of Directors will meet on May 7, 2026, to consider an investment in its unlisted material subsidiary, Biocon Biologics Limited (BBL). The investment will be through the purchase or acquisition of equity shares of BBL for consideration other than cash. This will involve the issuance and allotment of fully paid-up equity shares of Biocon on a preferential allotment basis through private placement. The company will seek shareholder approval via postal ballot.